Showing results (21-30 of 137) with videos related to
Sort By:
Pageof 14
Archives of Pathology & Laboratory Medicine|October 7, 2008
Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancerJennifer M Giltnane, Annette Molinaro, Huan Cheng, et al.Cancer|April 28, 2011
A phase 2 trial of dasatinib in advanced melanomaHarriet M Kluger, Arkadiuz Z Dudek, Carrie McCann, et al.Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|September 7, 2020
Do reminder emails and past due notifications improve patient completion and institutional data submission for patient-reported outcome measures?Stephanie L Pugh, Joseph P Rodgers, Jennifer Moughan, et al.International Journal of Radiation Oncology, Biology, Physics|June 27, 2020
Characteristics of Participation in Patient-Reported Outcomes and Electronic Data Capture Components of NRG Oncology Clinical TrialsStephanie L Pugh, Joseph P Rodgers, Katherine A Yeager, et al.Journal of the National Cancer Institute|November 20, 2003
Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomyKarla Kerlikowske, Annette Molinaro, Imok Cha, et al.Journal of Neurological Surgery. Part B, Skull Base|March 22, 2017
Cost-Effectiveness Analysis of Surgical versus Medical Treatment of ProlactinomasCorinna C Zygourakis, Brandon S Imber, Rebecca Chen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 14, 2011
Plasma markers for identifying patients with metastatic melanomaHarriet M Kluger, Kathleen Hoyt, Antonella Bacchiocchi, et al.Journal of Neuro-Oncology|September 6, 2014
Pure germinomas of the central nervous system: treatment strategies and outcomesAdam Schoenfeld, Daphne A Haas-Kogan, Annette Molinaro, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2007
Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcomeChristopher B Moeder, Jennifer M Giltnane, Malini Harigopal, et al.Journal of the National Cancer Institute. Monographs|February 24, 2025
When to adjust for multiplicity in cancer clinical trialsJoseph M Unger, Gina L Mazza, Mohamed I Elsaid, et al.Pageof 14